Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors

Fig. 3

Apremilast inhibits lipopolysaccharide (LPS)-induced TNF-α release via cyclic adenosine monophosphalphate (cAMP). a Western blot of PDE4 was performed in the Raw 264.7 cell line. b Raw 264.7 cells were incubated with increasing concentrations of apremilast 30 minutes before incubation with or without LPS 1 μM during 20 minutes. Intracellular cAMP levels were then measured as described under “Materials and methods”. c Western blot of p-cAMP responsive element binding protein (p-CREB) and CREB shows that apremilast promotes CREB phosphorylation after incubation with LPS 1 μg/ml for 30 minutes. d Cumulative concentration response curves to apremilast (6 nM−1 μM) were performed in the Raw 264.7 cells 30 minutes before incubation with LPS 1 μM during 4 h. IC50 values were determined as described under “Materials and methods”. Data represent means ± standard error of the mean of four independent experiments. Statistical analysis was performed by two-way ANOVA: apremilast ***P <0.001, LPS: not significant. PDE4 phosphodiesterase 4,

Back to article page